M3541

M3541 is a potent, selective, and orally bioavailable small molecule inhibitor of ataxia telangiectasia mutated kinase (ATM). It acts as an ATP-competitive inhibitor with an IC50 of approximately 0.25 nM, displaying high selectivity over other kinases such as ATR, DNA-PK, PI3K isoforms, and mTOR. M3541 inhibits ATM-mediated signaling pathways involved in the repair of DNA double-strand breaks (DSBs), thereby sensitizing tumor cells to DNA-damaging treatments like radiotherapy and certain chemotherapies. Preclinical studies demonstrated that M3541 enhances the efficacy of ionizing radiation and shows synergy with PARP and topoisomerase inhibitors. Developed by Merck KGaA (Darmstadt, Germany), M3541 has been evaluated in phase I clinical trials for use in combination with palliative radiotherapy for patients with solid tumors[2][6][8].

Other names

atm inhibitor m 3541